
## **Supplementary Online Content**

Williams SB, Howard LE, Foster ML, et al. Estimated costs and long-term outcomes of patients with high-risk non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin in the Veterans Affairs Health System. *JAMA Netw Open*. 2021;4(3):e213800. doi:10.1001/jamanetworkopen.2021.3800


- **eFigure 1.** Kaplan-Meier Curves for Disease-Free Survival, Overall and Stratified by Clinical Stage Group
- **eFigure 2.** Kaplan-Meier Curves for Time to All-Cause Mortality, Overall and Stratified by Clinical Stage Group
- **eTable 1.** Univariable and Multivariable Association Between Demographic and Disease Characteristics and Disease-Free Survival (n = 401)
- eTable 2. Kaplan-Meier Event-Free Survival Estimates From Time of BCG Initiation
- **eTable 3.** Comparisons of Number of Patients With Any Cost vs No Cost Stratified by Progression Status
- eTable 4. Association Between Progression Status and Costs (if Any)
- **eTable 5.** Health Care Cost Data From Time of BCG Induction Start Date and 30 and 90 Days After Cystectomy (n = 33)

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure 1.** Kaplan-Meier Curves for Disease-Free Survival, Overall and Stratified by Clinical Stage Group



**eFigure 2.** Kaplan-Meier Curves for Time to All-Cause Mortality, Overall and Stratified by Clinical Stage Group



**eTable 1.** Univariable and Multivariable Association Between Demographic and Disease Characteristics and Disease-Free Survival  $(n = 401)^*$ 

		Univariable		Multivariable	
	Events/N	HR (95% CI)	P-value	HR (95% CI)	P-value
Age at BCG	202/401	1.01 (0.99-1.02)	0.20	1.00 (0.99-1.02)	0.69
initiation					
Gender			0.44		0.64
Female	33/73	Ref.		Ref.	
Male	169/328	1.15 (0.80-1.66)		1.10 (0.75-1.60)	
Smoking			0.12		0.42
Current	63/145	Ref.		Ref.	
Former	111/199	1.37 (1.01-1.85)		1.25 (0.89-1.76)	
Never smoker	28/57	1.27 (0.82-1.96)		1.20 (0.76-1.91)	
CIS at High-Risk			< 0.001		< 0.001
NMIBC diagnosis					
No	151/333	Ref.		Ref.	
Yes	51/68	2.14 (1.56-2.94)		1.99 (1.44-2.75)	
CCI at BCG			0.08		0.22
initiation					
0-2	56/112	Ref.		Ref.	
3-4	96/173	1.35 (0.97-1.88)		1.21 (0.86-1.70)	
5+	50/116	0.96 (0.66-1.41)	-	0.90 (0.60-1.35)	

BCG= Bacillus Calmette-Guerin; CCI=Charlson comorbidity index; NMIBC=non-muscle invasive bladder cancer

<sup>\*</sup>Patients with BCG initiation prior to 2000 did not have CCI available and were therefore not included in this analysis

eTable 2. Kaplan-Meier Event-Free Survival Estimates From Time of BCG Initiation

	3	5	10	15
	years	years	years	years
Progression	88.1%	83.5%	78.2%	73.9%
CIS ± T1 or TaHG	81.8%	66.8%	60.0%	-
TaHG or T1, no CIS	89.4%	86.9%	82.2%	78.6%
Cystectomy	93.0%	89.7%	88.1%	88.1%
CIS ± T1 or TaHG	87.7%	79.2%	75.6%	-
TaHG or T1, no CIS	94.0%	91.8%	90.7%	90.7%
Death	86.6%	75.3%	52.8%	30.5%
CIS ± T1 or TaHG	88.2%	72.8%	49.3%	-
TaHG or T1, no CIS	86.2%	75.7%	54.7%	36.8%
BC death	97.6%	94.7%	92.15%	85.0%
CIS ± T1 or TaHG	98.5%	89.0%	86.5%	-
TaHG or T1, no CIS	97.4%	95.9%	93.6%	86.3%

BC=bladder cancer; BCG= Bacillus Calmette-Guerin; CIS=carcinoma in situ

**eTable 3.** Comparisons of Number of Patients With Any Cost vs No Cost Stratified by Progression Status

	# (%) cos	st > \$0.00			
	No Progression (N=330)	Progression (N=71)	P-value <sup>1</sup>	Odds Ratio (95% CI) <sup>2</sup>	P-value <sup>2</sup>
<b>Total costs</b>					
1-year	303 (92)	70 (99)	0.040	7.4 ( 0.8- 65.1)	0.072
2-year	308 (93)	71 (100)	0.019	NA	
5-year	328 (99)	71 (100)	>0.99	NA	
Inpatient costs					
1-year	54 (16)	25 (35)	<.001	3.2 ( 1.8- 5.8)	<.001
2-year	78 (24)	39 (55)	<.001	4.3 ( 2.5- 7.5)	<.001
5-year	143 (43)	61 (86)	<.001	8.2 ( 4.0- 16.6)	<.001
Outpatient cost s					
1-year	303 (92)	70 (99)	0.040	7.4 ( 0.8- 65.1)	0.072
2-year	308 (93)	71 (100)	0.019	NA	
5-year	328 (99)	71 (100)	>0.99	NA	
Laboratory cos ts					
1-year	300 (91)	68 (96)	0.235	2.2 ( 0.6- 8.1)	0.255
2-year	307 (93)	70 (99)	0.096	4.9 ( 0.6- 39.5)	0.140
5-year	327 (99)	71 (100)	>0.99	NA	
Pharmacy cost s					
1-year	302 (92)	67 (94)	0.628	1.4 ( 0.4- 5.1)	0.635
2-year	308 (93)	71 (100)	0.019	NA	
5-year	328 (99)	71 (100)	>0.99	NA	
Surgery costs					
1-year	187 (57)	44 (62)	0.430	1.5 ( 0.9- 2.7)	0.151
2-year	209 (63)	56 (79)	0.013	2.8 ( 1.4- 5.4)	0.002
5-year	256 (78)	68 (96)	<.001	7.2 ( 2.2- 23.7)	0.001
Radiology cost s					

1-year	242 (73)	57 (80)	0.293	1.7 ( 0.9- 3.3)	0.122
2-year	276 (84)	67 (94)	0.024	4.0 ( 1.3- 11.9)	0.014
5-year	311 (94)	69 (97)	0.555	2.2 ( 0.5- 10.0)	0.293

<sup>&</sup>lt;sup>1</sup> Fisher's exact test
<sup>2</sup> Odds Ratio of any cost vs. no cost controlling for age at BC diagnosis, race (white, black, other), gender, and year of BC diagnosis

	Median (25 <sup>th</sup> percent	tile – 7 <sup>th</sup> percentile)			
	No Progression	Progression	P-value <sup>1</sup>	Coefficient <sup>2</sup>	P-value
	(N=330)	(N=71)			
Total costs					
1-year	29,808 (16,732-50,299)	37,654 (19,550-6,595)	0.007	1.56	< 0.001
2-year	54,422 (29,456-84,264)	104,289 (49,108- 18,3485)	<.001	2.01	<0.001
5-year	95,565 (52,751-174,119)	233,960 (157,328- 346,579)	<.001	2.48	<0.001
Inpatient costs		, ,			
1-year	20,232 (7,519-37,148)	53,801 (13,526-85,729)	0.008	2.33	0.006
2-year	20,153 (7,719-41,773)	57,002 (21,818- 108,524)	<.001	2.79	<0.001
5-year	30,609 (11,116-65,735)	82,824 (52,504- 115,695)	<.001	2.58	<0.001
Outpatient costs		,			
1-year	27,936 (16,543-46,480)	34,885 (18,876-72,253)	0.014	1.35	0.007
2-year	51,241 (28,700-81,083)	72,323 (49,108- 133,648)	<.001	1.64	<0.001
5-year	88,874 (50,130-143,706)	,	<.001	1.97	<0.001
Laboratory cost	S	,			
1-year	1,152 (562-2,314)	1,932 (870-6,047)	<.001	2.20	< 0.001
2-year	2,151 (1,161-4,062)	4,333 (2,379-11,738)	<.001	2.59	< 0.001
5-year	4,117 (2,109-7,879)	13,279 (6,952-20,123)	<.001	2.98	< 0.001
Pharmacy costs					
1-year	2,225 (1,089-4,679)	3,699 (1,437-7,500)	0.009	1.74	0.001
2-year	4,054 (1,796-8,571)	7,536 (2,667-23,308)	<.001	1.92	< 0.001
5-year	7,217 (3,653-17,949)	18,306 (10,210-39,045)	<.001	2.63	< 0.001
Surgery costs					
1-year	5,955 (2,779-9,688)	11,934 (4,952-34,811)	<.001	2.43	< 0.001
2-year	9,645 (4,507-15,778)	18,789 (11,159-40,461)	<.001	2.37	< 0.001
5-year	13,813 (6,629-29,161)	34,468 (18,104-67,055)	<.001	2.71	< 0.001
Radiology costs	,	, , , , , , , , , , , , , , , , , , ,			
1-year	822 (383-1,671)	1,144 (418-3,230)	0.015	1.77	0.002
2-year	1,348 (627-2,852)	3,002 (1,230-11,055)	<.001	2.84	< 0.001
5-year	2,950 (1,340-5,879)	11,395 (4,990-19,851)	<.001	3.75	< 0.001

	Median (25 <sup>th</sup> percent	ile – 7 <sup>th</sup> percentile)				
	No Progression	Progression	P-value <sup>1</sup>	Coefficient <sup>2</sup>	P-value	
	(N=330)	(N=71)				
<sup>2</sup> General linear regression on the logarithm of the costs controlling for age at BC diagnosis, rac						
(white, black, other), gender, and year of BC diagnosis. The coefficient of progression relative t						
no progression was the exponential estimate of the logarithm of the costs.						

**eTable 5.** Health Care Cost Data From Time of BCG Induction Start Date and 30 and 90 Days After Cystectomy  $(n = 33)^*$ 

Age at BC diagnosis	66 (61, 74)			
Race				
Black	2 (6%)			
White	30 (91%)			
Other	1 (3%)			
Ethnicity				
Hispanic/Latino	1 (3%)			
Not Hispanic/Latino	32 (97%)			
Gender				
Female	10 (30%)			
Male	23 (70%)			
Year of BC diagnosis	2010 (2007, 2013)			
	Costs in USD			
	From BCG start to	30 days post	90 days post	
	follow-up	cystectomy	cystectomy	
Total costs	358,593	89,131	89,889	
	(257,699, 652,853)	(66,892, 117,921)	(72,497, 127,960)	
Inpatient costs	101,768	63,441 (53,801, 84,544)	-	
	(69,755, 195,203)			
Outpatient costs	235,083	15,218 (7,264, 31,642)	26,397 (11,577, 39,253)	
	(179,086, 440,244)			
Laboratory costs	18,468	7,367 (4,537, 10,888)	7,495 (4,563, 10,888)	
•	,	7,307 (4,337, 10,000)	7,475 (4,505, 10,666)	
·	(11,529, 27,835)	7,307 (4,337, 10,666)	7,473 (4,303, 10,000)	
Pharmacy costs	,	5,107 (3,477, 13,075)	5,993 (4,171, 18,897)	
·	(11,529, 27,835)	, , , , , ,		
·	(11,529, 27,835) 32,933	, , , , , ,		
Pharmacy costs	(11,529, 27,835) 32,933 (16,532, 68,596)	5,107 (3,477, 13,075)		
Pharmacy costs	(11,529, 27,835) 32,933 (16,532, 68,596) 76,184	5,107 (3,477, 13,075)		

BC=bladder cancer; BCG= Bacillus Calmette-Guerin; USD: United States Dollar

All costs are adjusted to 2019 USD using the medical component of the Consumer Price Index (mCPI)

Summary statistics for continuous variables display median (25<sup>th</sup> percentile, 75<sup>th</sup> percentile)

\*Six patients who received their cystectomy outside of the VA were not included in this table